In 2004 the UK based drug company Pharmion, Celgene’s licensee partner in Europe, submitted a drug application at the European Medicines Agency to sell and market Thalidomide for the treatment of multiple myeloma in Europe. (Pharmion was bought by Celgene in 2008.)

Source: Der Spiegel: Dem Tumor den Saft abdrehen, October 18, 2004.

USA - FDA approves use to treat ENLApplication for T ... er the European marketUSA - FDA approve ... nt of multiple myeloma